http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#Head
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#assertion
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#provenance
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#pubinfo
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#assertion
http://purl.obolibrary.org/obo/DOID_3393
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_3393
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00952
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#association
http://www.w3.org/2000/01/rdf-schema#label
"Naratriptan tablets are contraindicated in patients with: Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal's angina [see Warnings and Precautions (5.1) ] Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions (5.2) ] History of stroke or transient ischemic attack (TIA) or history of hemiplegic or basilar migraine because such patients are at a higher risk of stroke [see Warnings and Precautions (5.4) ] Peripheral vascular disease [see Warnings and Precautions (5.5) ] Ischemic bowel disease [see Warnings and Precautions (5.5) ] Uncontrolled hypertension [see Warnings and Precautions (5.8) ] Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide) [see Drug Interactions (7.1, 7.2)] Hypersensitivity to naratriptan (angioedema and anaphylaxis seen) [see Warnings and Precautions (5.9)] Severe renal or hepatic impairment [see Use in Specific Populations (8.6, 8.7), Clinical Pharmacology (12.3)] History of coronary artery disease or coronary artery vasospasm (4) Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders (4) History of stroke, transient ischemic attack, or hemiplegic or basilar migraine (4) Peripheral vascular disease (4) Ischemic bowel disease (4) Uncontrolled hypertension (4) Recent (within 24 hours) use of another 5-HT 1 agonist (e.g., another triptan) or an ergotamine-containing medication (4) Hypersensitivity to naratriptan (angioedema and anaphylaxis seen) (4) Severe renal or hepatic impairment (4)"
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#association
https://w3id.org/biolink/vocab/relation
https://schema.org/MedicalContraindication
https://identifiers.org/drugbank:DB00952
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#provenance
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#pubinfo
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#sig
http://purl.org/nanopub/x/hasSignature
bwa6+y4PCAIPfPKOhAyb7wKM7cxcR9Xjm9OT2Rj5+7nGLjda8LVOqgl5YHrWokVGmeK0vgrsWNYo3R1hVPu50qGi7GMFStP5ttW+ZrirW3/pyQGxD1H8q7t0TPX+Ki9VfrG7a9sDZ79rW5XgARuE4PaSagmd1bTt03qpJMChqP0=
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ
http://purl.org/dc/terms/created
2021-08-23T18:30:22.832+02:00
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAV-uYtAmJH2lGwVWQDa-0-4zmHVvAfZfTeSvq8TvQyOQ
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY